X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

High Mortality Due To VEXAS Than What Was Previously Thought

Content Team by Content Team
28th January 2023
in News, Research & Development

As per a recent study that was published in JAMA, a not so well-known syndrome with high mortality has a much higher prevalence than it was thought. The syndrome called VEXAS was first identified in 2020 in patients who had some unexplained fevers, inflammation, and anaemia. One of the lead investigators of the research, David Beck, M.D., Ph.D., also led a team that initially identified the UBA1 mutation of the gene that was shared amongst the patients with VEXAS.

The team made use of the knowledge to analyse the DNA blood records of around 163,096 patients who consented to be part of the Pennsylvania healthcare system. This mutation was found in nine males as well as two females.

Although these numbers shed some light on the fact that this is a rare disease, the previous study in 2020 identified only 25 men and no women with this condition in the US. The new study, which was led by NYU Grossman School of Medicine researchers, puts forth the fact that the rare condition happens to be more vexing than it was originally thought to be. Apparently, 1 in 4269 men and 1 in 26238 women were over 50.

As per one of the rheumatologists, Mathew Koster, MD, from a leading clinic, the findings were indeed remarkable. According to him, VEXAS is more common than one thinks.

Proving the fact that its prevalence happens to be greater in men is of particular significance as it carries a pretty high mortality number. It is well to be noted that almost half of the population, mostly men, die from VEXAS within 5 years of its detection.

From what one could see, there was a lack of diversity in the study, as 94% happened to be white and 61% were female, all based out of Pennsylvania. The team is looking forward to analysing a more racially diverse group and, at the same time, looking into other genetic causes.

As per the team, these findings are bound to raise awareness, thereby increasing accuracy of diagnosis and opening new doors to novel therapies. According to Beck, many patients who were diagnosed with other inflammatory syndromes did not quite fit the pattern or find the treatments worthwhile. By way of testing VEXAS subgroups, doctors will be able to target the most accurate treatments for patients. The development of a simple blood test for the UBA1 mutation is also a priority so as to make for an easier and earlier diagnosis.

As far as the current treatments for the disease go, they include high-dosage steroids, JANUS kinase inhibitors, and in some instances, bone marrow transplants to put a brake on the symptoms. Since the genetic mutation is in the blood, a bone marrow transplant is a curative treatment but possesses a considerable risk as well.

The next steps when it comes to Beck’s team include a partnership with the NIH to look further into the drivers that make VEXAS more harmful in certain patients.

Beck is anticipating that the research efforts will get attention from the field of biopharma for more treatments now that it is known that the disease is more prevalent than previously thought. Since the disease is driven by gene mutations, gene therapy can be considered for it.

Previous Post

WHO Asks For Supply Chain Alterations To Fight Contamination

Next Post

New Algorithms That Lead To Personalized Cancer Treatments

Related Posts

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Drugs Gain From Tardigrade Proteins, Says Research
Drug Development

Pharma Drugs Gain From Tardigrade Proteins, Says Research

22nd March 2023
Next Post

New Algorithms That Lead To Personalized Cancer Treatments

Latest News

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In